Xeris Biopharma Holdings, Inc. Logo

Xeris Biopharma Holdings, Inc.

Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.

XERS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1375 WEST FULTON STREET, SUITE 1300, 60607 CHICAGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, ready-to-use injectable and infusible drug formulations. The company utilizes its proprietary technology platforms to create therapies that are easier for patients and caregivers to use, aiming to reduce treatment burdens and overall healthcare costs. Xeris concentrates on addressing unmet medical needs in various therapeutic areas, with a particular focus on chronic endocrine, metabolic, and other rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Xeris Biopharma Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Xeris Biopharma Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Xeris Biopharma Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany
PA8

Talk to a Data Expert

Have a question? We'll get back to you promptly.